Atria Investments’s Nuvation Bio NUVB Stock Holding History

Atria Investments’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-21,602	Closed	-$42.1K	–	2118
2025 Q2	$42.1K	Buy	+21,602	New	+$45K	﹤0.01%	1977

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Atria Investments's NUVB Position: Q3 2025 in Review

Atria Investments sold out of Nuvation Bio (NUVB) in Q3 2025, closing a stake of 21,602 shares — an estimated $42.1K sold.

Atria Investments first reported a position in NUVB in Q2 2025 and held it in 1 quarter. The position peaked at $42.1K in Q2 2025. 203 funds tracked by Wall St. Rank hold NUVB as of Q3 2025.

Atria Investments reported no remaining Nuvation Bio position as of Q3 2025 after selling out during the quarter.
Atria Investments sold 21,602 Nuvation Bio shares in Q3 2025, an estimated $42.1K.
Atria Investments first reported a position in Nuvation Bio in Q2 2025 and held it in 1 quarter.
Atria Investments's Nuvation Bio position peaked at $42.1K in Q2 2025.
203 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2025.

Based on Atria Investments's 13F filing for Q3 2025, filed 6 Nov 2025.